Chemomab Therapeutics Ltd. Sponsored ADR CMMB 深 沪
已收盘 08-01 16:00:00 美东时间
1.025
-0.045
-4.21%
华盛通- 最 高1.07
- 今 开1.07
- 成交量 10.63万股
- 最 低 1.02
- 昨 收 1.07
- 总市值 1964.29万
- 52周最高 2.55
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.8905
- 委 比 -60.48%
- 总股本 1916.38万
- 历史最高 184.00
- 量 比 0.94
- 振 幅 4.67%
- 历史最低 0.42
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Chemomab Therapeutics Enters Sales Agreement with LifeSci Capital
The latest announcement is out from Chemomab Therapeutics ( ($CMMB) ). On July ...
07-26 04:55
中播数据（00471.HK）7月24日收盘平盘
证券之星消息，截至2025年7月24日收盘，中播数据(00471.HK)报收于0.62港元，与上一交易日持平，成交量12.8万股，成交额7.87万港元。
07-24 17:57
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
Chemomab Therapeutics Ltd. presented Phase 2 SPRING trial data at BSG Live’25, highlighting nebokitug's potential as a first-in-class treatment for primary sclerosing cholangitis (PSC). Results showed the drug was safe, well-tolerated, and linked to improvements in biomarkers, suggesting disease-modifying effects. This supports advancing to Phase 3 trials.
06-30 12:00
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
<p>Chemomab Therapeutics Ltd）宣布，其双活性单抗药物Nebokitug在治疗原发性硬化性胆管炎（PSC）上取得了两项关键进展：获FDA对CMC（化学、制造和控制）及非临床毒理学研究方案的确认；毒理学研究可与其PSC 3期临床试验同步进行，并将作为BLA申请的一部分提交。公司正为PSC 3期临床试验做准备，同时与潜在战略伙伴持续洽谈。</p>
06-11 12:00
中播数据（00471.HK）6月10日收盘跌5.26%
证券之星消息，截至2025年6月10日收盘，中播数据(00471.HK)报收于0.54港元，下跌5.26%，成交量74.7万股，成交额42.2万港元。
06-10 17:56
Chemomab Therapeutics' Lead Product Nebokitug Awarded New Patent Protections In China And Russia
—New Patents Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in China and Russia Providing Coverage Up To 2041——Further Expands Protections Provided by
06-03 20:09
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
Chemomab Therapeutics announced that its lead product nebokitug has received new patent protections in China and Russia. These patents cover the use of nebokitug for treating liver diseases, including primary sclerosing cholangitis (PSC), with coverage extending up to 2041. The grants further expand nebokitug's intellectual property portfolio, which already includes patents in the U.S., Europe, Japan, and other key regions. The company plans to a...
06-03 12:00
中播数据（00471.HK）5月29日收盘涨3.45%，主力资金净流入17.4万港元
资金流向数据方面，5月29日中播数据主力资金净流入17.4万港元，无超大单资金净流入，大单资金净流入17.4万港元，中单资金净流出4362.0港元，小单资金净流入609.0港元。
05-29 17:57
Chemomab Therapeutics Advances Nebokitug for PSC Treatment
Chemomab Therapeutics Ltd. ( ($CMMB) ) has released its Q1 earnings. Here is a ...
05-17 11:53
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
